Funding for this research was provided by:
National Institutes of Health (HL007188, HL087000, HL078522, HL079233, HL094100, HL087708, CA127642, CA068484, HL053392, HD52102, HD052104, HL072705, AI50274, HL004537, HD80002, HL095127)
National Heart, Lung, and Blood Institute (R01 HL109090, R01 HL53392, R01 HL111459)
Children's Cardiomyopathy Foundation (n/a)
Lance Armstrong Foundation (n/a)
Stop! Children's Cancer of Palm Beach County (n/a)
Women’s Cancer Association (n/a)
Parker Family Foundation (n/a)
Scott Howard Fund (n/a)
Michael Garil Fund (n/a)
Sofia's Hope (n/a)
Kyle John Rymiszewski Foundation (n/a)
Received: 10 October 2018
Accepted: 20 January 2019
First Online: 29 January 2019
Ethics approval and consent to participate
: Lahey Clinic, Inc. IRB has approved the project and waived the requirement for consent.
: Not applicable. (This manuscript does not contain any identifiable individual information and Lahey Clinic, Inc. IRB has waived the requirement for consent).
: Dr. Lipshultz is a consultant for Clinigen Group plc, which manufactures dexrazoxane. Dr. Lipshultz has received investigator-initiated research grants from Pharmacia and Upjohn, Chiron Corporation, and Pfizer to study dexrazoxane.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.